Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
Caterina Caminiti,
Giuseppe Maglietta,
Laura Arenare,
Raimondo Di Liello,
Gessica Migliaccio,
Daniela Barberio,
Michelino De Laurentiis,
Francesca Di Rella,
Francesco Nuzzo,
Carmen Pacilio,
Giovanni Iodice,
Michele Orditura,
Fortunato Ciardiello,
Sara Di Bella,
Luigi Cavanna,
Camillo Porta,
Filippo Giovanardi,
Carla Ida Ripamonti,
Domenico Bilancia,
Giuseppe Aprile,
Tommaso Ruelle,
Francesca Diodati,
Maria Carmela Piccirillo,
Elisabetta Iannelli,
Carmine Pinto,
Francesco Perrone
Affiliations
Caterina Caminiti
Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy
Giuseppe Maglietta
Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy
Laura Arenare
Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Raimondo Di Liello
Division of Medical Oncology, Ospedale del Mare, Napoli, Italy
Gessica Migliaccio
Departmental Structure of Clinical Psycho-oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
Daniela Barberio
Departmental Structure of Clinical Psycho-oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
Michelino De Laurentiis
Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Francesca Di Rella
Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Francesco Nuzzo
Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Carmen Pacilio
Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Giovanni Iodice
Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Michele Orditura
Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
Fortunato Ciardiello
Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
Sara Di Bella
Medical Oncology, ASST Rhodense, Rho (MI), Italy
Luigi Cavanna
Medical Oncology, Ospedale Guglielmo da Saliceto, Piacenza, Italy
Camillo Porta
Interdisciplinary Department of Medicine, Università degli Studi ‘A. Moro’, Bari, Italy; Polyclinic Consortium University Hospital, Bari, Italy
Filippo Giovanardi
Medical Oncology, Ospedale Civile, Guastalla (RE), Italy
Carla Ida Ripamonti
Supportive Care Unit, istituto Nazionale Tumori, IRCCS, Milano, Italy
Domenico Bilancia
Medical Oncology, Ospedale S.Carlo, Potenza, Italy
Giuseppe Aprile
Medical Oncology, Azienda ULSS 8 Nerica, Ospedale S.Bortolo, Vicenza, Italy
Tommaso Ruelle
Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DIMI), Università di Genova, Genova, Italy
Francesca Diodati
Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy
Maria Carmela Piccirillo
Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy
Elisabetta Iannelli
FAVO - Federazione Italiana delle Associazioni di Volontariato in Oncologia, Roma, Italy
Carmine Pinto
Medical Oncology, AUSL-IRCCS, Reggio Emilia, Italy
Francesco Perrone
Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy; Corresponding author. Clinical Trial Unit Istituto Nazionale Tumori IRCCS Fondazione G.Pascale, Italy.
Patients’ self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients.Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) are a tool allowing direct patients’ reporting of side-effects.We tested psychometric properties of a selected list of PRO-CTCAE items, in a cohort of 303 breast cancer patients, using validated instruments for quality of life assessment as anchors.The analysis of convergent validity with HADS (Hospital Anxiety and Depression Scale) and EORTC BR-23 sub-scales, and the analysis of responsiveness with the PGIC (Patients Global Impression of Change) score supported that a selected list of PRO-CTCAE symptoms might represent a standardized, agile tool for both research and practice settings to reduce patient burden without missing relevant information on patient perceptions.Among patients using digital devices, those with a higher education levels required shorter time to fulfil questionnaires.In conclusion, a selected list of PRO-CTCAE items can be considered as a standardized, agile tool for capturing crucial domains of side-effects and quality of life in patients with breast cancer.The study is registered on clinicaltrials.gov (NCT04416672).